UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
B lymphocyte depletion therapy in autoimmune disorders: Chasing trojan Horses
  • Publication Type:
    Chapter
  • Authors:
    Edwards JCW, Cambridge G, Leandro MJ
  • Publication date:
    01/01/2005
  • Pagination:
    291, 311
  • ISBN-10:
    0387245332
  • ISBN-13:
    9780387245331
  • Status:
    Published
  • Book title:
    Molecular Autoimmunity
Abstract
Since the anti-CD20 therapeutic monoclonal antibody rituximab became available for clinical use in 1997 the effects of B lymphocyte depletion (BLyD) have been explored in a range of autoimmune disorders (Edwards et al., 2002). The results of a formal controlled trial in rheumatoid arthritis (RA) confirm that clinical benefit can be substantial (Edwards et al., 2004). Perhaps more significantly in the long term, the opportunity afforded by BLyD to study mechanisms underlying pathogenesis of many human autoimmune diseases is unique and exciting. This chapter reviews the rationale for BLyD in the context of changing ideas about the role of B cells in autoimmunity, and explores the emerging concept of autoimmune B cells as immunologic Trojan horses. The potential for clinical application, the logistics employed, and the clinical results obtained with rituximab so far are reviewed. Finally, evolving immunodynamic studies are described, which highlight correlations between clinical state and autoantibody profiles, and which may elucidate mechanisms of action and point to means of optimization of therapeutic benefit and development of further targeted approaches to therapy. © 2005 Springer Science+Business Media, Inc.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Inflammation
Author
Div of Medicine
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by